Chronic Lung Injury After Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer

被引:4
|
作者
Soh, Junichi
Sugimoto, Seiichiro
Namba, Kei
Miura, Akihiro
Shiotani, Toshio
Yamamoto, Haruchika
Suzawa, Ken
Shien, Kazuhiko
Yamamoto, Hiromasa
Okazaki, Mikio
Katsui, Kuniaki
Yamane, Masaomi
Kiura, Katsuyuki
Kanazawa, Susumu
Toyooka, Shinichi
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gen Thorac Surg & Breast & Endocrinol Surg, Okayama, Japan
[2] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osaka, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Organ Transplant Ctr, Okayama, Japan
[4] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Proton Beam Therapy, Okayama, Japan
[5] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Resp Med, Okayama, Japan
[6] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Radiol, Okayama, Japan
来源
ANNALS OF THORACIC SURGERY | 2021年 / 112卷 / 01期
关键词
PREDICTING RADIATION PNEUMONITIS; CONCURRENT CHEMORADIOTHERAPY; SURGERY; RISK; CHEMORADIATION; POLYMORPHISMS; PARAMETERS; CISPLATIN; DOCETAXEL;
D O I
10.1016/j.athoracsur.2020.07.068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Trimodality therapy is a treatment option for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Thoracic radiation has both early (radiation pneumonitis) and late (chronic lung injury [CLI]) adverse effects on the lung. While CLI is expected to result in various problems in long-term survivors, these manifestations have not been precisely investigated. Methods. We enrolled 112 LA-NSCLC patients who had received induction chemoradiotherapy followed by surgery, and then undergone follow-up computed tomography (CT) every 6 months for greater than 1 year. All chest CT images were reviewed to evaluate any injury of the pulmonary parenchyma. Results. CLI at 1 year after surgery and its progression were observed in 94 (84%) and 38 (34%) patients, respectively. Progressive lung fibrosis as the first manifestation of CLI progression was most frequent after right middle and lower lobectomy. Cavity formation was the subsequent manifestation after progressive lung fibrosis, and chronic infection was the final stage of CLI. The cumulative rate of chronic infection was 76.4% at 10 years in patients with cavity formation. Ten patients with chronic infection included 7 cases of pulmonary aspergillosis and 2 cases of cavity infections with methicillin-resistant Staphylococcus aureus or Stenotrophomonas maltophilia. Among them, 4 patients required surgical interventions including completion pneumonectomy or fenestration. Conclusions. CLI is a common incidence after trimodality therapy for LA-NSCLC. CLI frequently results in cavity formation, which is a precursor of highly refractory chronic infections requiring surgical intervention. Appropriate management needs to be established for CLI developing after trimodality therapy. (Ann Thorac Surg 2021;112:279-88) (c) 2021 by The Society of Thoracic Surgeons
引用
收藏
页码:279 / 288
页数:10
相关论文
共 50 条
  • [1] Trimodality therapy for locally advanced non-small cell lung cancer
    Lackner, R. P.
    Ganti, A.
    Zhen, W.
    Copur, M. S.
    Vaziri, I. A.
    Bolton, M.
    Hlavaty, T.
    Trujillo, K. P.
    Kessinger, M. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Optimal Timing of Trimodality Therapy in Locally Advanced Non-Small Cell Lung Cancer
    Han, J.
    Hasan, S.
    Choi, I. J.
    Press, R. H.
    Simone, C. B., II
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E150 - E150
  • [3] Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer
    Kuniaki Katsui
    Takeshi Ogata
    Kenta Watanabe
    Kotaro Yoshio
    Masahiro Kuroda
    Masaomi Yamane
    Takao Hiraki
    Katsuyuki Kiura
    Shinichi Toyooka
    Susumu Kanazawa
    [J]. International Journal of Clinical Oncology, 2021, 26 : 1450 - 1460
  • [4] Role of particle beam therapy in a trimodality approach to locally advanced non-small cell lung cancer
    Kesarwala, Aparna H.
    Grover, Surbhi
    Rengan, Ramesh
    [J]. THORACIC CANCER, 2013, 4 (02) : 95 - 101
  • [5] Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer
    Katsui, Kuniaki
    Ogata, Takeshi
    Watanabe, Kenta
    Yoshio, Kotaro
    Kuroda, Masahiro
    Yamane, Masaomi
    Hiraki, Takao
    Kiura, Katsuyuki
    Toyooka, Shinichi
    Kanazawa, Susumu
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (08) : 1450 - 1460
  • [6] Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC): Predictors of Surgical Drop Out
    Liriano, M.
    Nichols, E. M.
    Morris, C. G.
    Burrows, W.
    Battafarano, R. J.
    Garofalo, M. C.
    Turner, M.
    Suntharalingam, M.
    Edelman, M. J.
    Feigenberg, S. J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S173 - S174
  • [7] Optimal surgical timing and radiotherapy dose for trimodality therapy in locally advanced non-small cell lung cancer
    Han, James E.
    Hasan, Shaakir
    Choi, J. Isabelle
    Press, Robert H.
    Simone, Charles B., II
    [J]. CANCER MEDICINE, 2021, 10 (17): : 5794 - 5808
  • [8] Trimodality Therapy for Locally Advanced Non-Small-Cell Lung Cancer: A Curative Approach
    Stupp, Roger
    Betticher, Daniel
    Ris, Hans-Beat
    Peters, Solange
    Pless, Miklos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : E118 - E119
  • [9] Proton therapy for locally advanced non-small cell lung cancer
    Gjyshi, Olsi
    Liao, Zhongxing
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2020, 93 (1107):
  • [10] Adjuvant therapy for locally advanced non-small cell lung cancer
    Keller, SM
    [J]. LUNG CANCER, 2003, 42 : S29 - S34